

**Supplementary Table S2: Protection against severe COVID-19 disease at presentation by receipt of complete regimens of vaccines**

\*

	Severe cases		Severe controls		Protective effectiveness (PE) % (95% confidence interval, CI)			
	<i>Vaccinees</i>	<i>Non-vaccinees</i>	<i>Vaccinees</i>	<i>Non-vaccinees</i>	<i>Crude PE</i>	<i>p-value</i>	<i>Adjusted PE</i>	<i>p-value</i>
<b>Any vaccine<sup>‡</sup></b>	3	24	10	35	56(-76,89)	0.244	80 (-3, 98) <sup>‡</sup>	0.079
<b>Serum Institute of India (ChAdOx1 nCoV- 19)</b>	2	24	1	35	-192(-3300,75)	0.393	-41 (-4220, 96) <sup>‡</sup>	0.827
<b>Sinopharm (Vero Cell-inactivated)</b>	1	24	6	35	76(-115,97)	0.203	87 (-8, 99) <sup>‡</sup>	0.098
<b>Moderna (mRNA-1273)</b>	0	24	3	35	100(-Inf,100)	0.991	100(-Inf,100) <sup>‡</sup>	0.996

\*Received 2<sup>nd</sup> dose of vaccine at least 14 days before presentation

<sup>†</sup>Adjusted by: forced variables (age in years, study month of presentation, and study site and other covariates which were significantly associated at p<0.05 in the stepwise model

<sup>‡</sup>Body mass index any, Serum Institute of India, Moderna

<sup>‡</sup>Any vaccine (Serum Institute of India (ChAdOx1 nCoV-19), Sinopharm (Vero Cell- inactivated), Moderna (mRNA-1273))